Inovio submits conditional EU marketing application for VOCERYQ in adults with RRP
INO•Inovio submitted a conditional marketing authorization application to the European Medicines Agency for VOCERYQ in adults with recurrent respiratory papillomatosis. The company said VOCERYQ is expected to be available in the U.S. in 60 days, with a full launch in Q1 2027.




